Lilly Gets Its Wish: STAR Results Show Evista Reduces Breast Cancer Risk
Trial shows Lilly’s Evista reduces risk of developing invasive breast cancer by 50%, comparable to AstraZeneca’s Nolvadex.
Trial shows Lilly’s Evista reduces risk of developing invasive breast cancer by 50%, comparable to AstraZeneca’s Nolvadex.